361 related articles for article (PubMed ID: 28452111)
1. Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies.
Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Zhang W; Yang L; Yan Y; Lin J; Qian J
J Cell Mol Med; 2017 Aug; 21(8):1468-1481. PubMed ID: 28452111
[TBL] [Abstract][Full Text] [Related]
2. ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome.
Wang H; Wang XQ; Xu XP; Lin GW
Leuk Res; 2010 May; 34(5):598-604. PubMed ID: 19853913
[TBL] [Abstract][Full Text] [Related]
3.
Zhou JD; Li XX; Zhang TJ; Xu ZJ; Zhang ZH; Gu Y; Wen XM; Zhang W; Ji RB; Deng ZQ; Lin J; Qian J
Aging (Albany NY); 2019 May; 11(10):3376-3391. PubMed ID: 31147526
[No Abstract] [Full Text] [Related]
4. [Methylation status of id4 gene promoter in patients with chronic myeloid leukemia].
Wang XR; Kang HY; Cen J; Li YH; Wang LL; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1402-4. PubMed ID: 21176338
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
Zhao X; Tian X; Kajigaya S; Cantilena CR; Strickland S; Savani BN; Mohan S; Feng X; Keyvanfar K; Dunavin N; Townsley DM; Dumitriu B; Battiwalla M; Rezvani K; Young NS; Barrett AJ; Ito S
Br J Haematol; 2016 Nov; 175(3):427-439. PubMed ID: 27433923
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of the quantitative detection of ID4 gene methylation in myelodysplastic syndrome.
Kang H; Wang X; Gao L; Cen J; Li M; Wang W; Wang N; Li Y; Wang L; Yu L
Eur J Med Res; 2015 Feb; 20(1):16. PubMed ID: 25889027
[TBL] [Abstract][Full Text] [Related]
7. Differential methylation pattern of ID4, SFRP1, and SHP1 between acute myeloid leukemia and chronic myeloid leukemia.
Uhm KO; Lee ES; Lee YM; Park JS; Kim SJ; Kim BS; Kim HS; Park SH
J Korean Med Sci; 2009 Jun; 24(3):493-7. PubMed ID: 19543515
[TBL] [Abstract][Full Text] [Related]
8. Methylation-independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia.
Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Yao DM; Zhang W; Lin J; Qian J
J Cell Physiol; 2018 Jun; 233(6):4707-4714. PubMed ID: 29115660
[TBL] [Abstract][Full Text] [Related]
9. [Study on the correlation between Chinese medical syndrome types and ID4 gene promoter methylation in human acute myeloid leukemia].
Liu F; Xu RR
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Apr; 32(4):471-3. PubMed ID: 22803425
[TBL] [Abstract][Full Text] [Related]
10. Identification and validation of SRY-box containing gene family member
Zhou JD; Wang YX; Zhang TJ; Li XX; Gu Y; Zhang W; Ma JC; Lin J; Qian J
Clin Epigenetics; 2018; 10():92. PubMed ID: 30002740
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic epigenetics: an emerging clinical approach to hematologic malignancies.
Clin Adv Hematol Oncol; 2005 Mar; 3(3 Suppl 1):1-10; quiz 11-2. PubMed ID: 21438190
[No Abstract] [Full Text] [Related]
12. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
Lübbert M; Ihorst G; Sander PN; Bogatyreva L; Becker H; Wijermans PW; Suciu S; Bissé E; Claus R
Br J Haematol; 2017 Feb; 176(4):609-617. PubMed ID: 27905102
[TBL] [Abstract][Full Text] [Related]
13. Expression pattern and prognostic implication of SALL4 gene in myeloid leukemias: a case-control study.
Farawela HM; Zawam HM; Al-Wakeel HA; El-Nagdy MH; El-Refaey FA; Abdel-Rahman HA
Scand J Clin Lab Invest; 2019; 79(1-2):65-70. PubMed ID: 30638095
[TBL] [Abstract][Full Text] [Related]
14. [Clinical observation of decitabine-treating patients with myelodysplastic syndrome and acute myeloid leukemia].
Yang H; Zhu HY; Jiang MM; Wang QS; Han XP; Huang WR; Jing Y; Wang SH; Zhang SS; Mei JH; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):121-5. PubMed ID: 23484704
[TBL] [Abstract][Full Text] [Related]
15. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
Grövdal M; Karimi M; Khan R; Aggerholm A; Antunovic P; Astermark J; Bernell P; Engström LM; Kjeldsen L; Linder O; Nilsson L; Olsson A; Holm MS; Tangen JM; Wallvik J; Oberg G; Hokland P; Jacobsen SE; Porwit A; Hellström-Lindberg E
Br J Haematol; 2010 Aug; 150(3):293-302. PubMed ID: 20497178
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.
Cabrero M; Jabbour E; Ravandi F; Bohannan Z; Pierce S; Kantarjian HM; Garcia-Manero G
Leuk Res; 2015 May; 39(5):520-4. PubMed ID: 25828745
[TBL] [Abstract][Full Text] [Related]
17. Hypermethylation of ITGBL1 is associated with poor prognosis in acute myeloid leukemia.
Lian XY; Ma JC; Zhou JD; Zhang TJ; Wu DH; Deng ZQ; Zhang ZH; Li XX; He PF; Yan Y; Lin J; Qian J
J Cell Physiol; 2019 Jun; 234(6):9438-9446. PubMed ID: 30317626
[TBL] [Abstract][Full Text] [Related]
18. [ID4 promoter methylation in acute myeloid leukemia].
Xu RR; Liu F; Cui X; Zhang XW; Wang Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):582-4. PubMed ID: 21729527
[TBL] [Abstract][Full Text] [Related]
19. Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia.
Zhou JD; Lin J; Zhang TJ; Ma JC; Li XX; Wen XM; Guo H; Xu ZJ; Deng ZQ; Zhang W; Qian J
J Cell Physiol; 2018 Mar; 233(3):2444-2450. PubMed ID: 28776669
[TBL] [Abstract][Full Text] [Related]
20. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]